18Fluorodeoxyglucose PET in schizophrenia.
Six chronic schizophrenic patients and six age-matched controls were studied with 18fluorodeoxyglucose (18FDG) positron emission tomography (PET). All patients were scanned when they had been free of medication for at least 2 weeks. Comparisons were made between the groups on regional ratios of cortical 18FDG, with manual and automated measures. Only one of eight regions, the right temporal cortical region, showed a significant group difference, and this effect was not significant when adjustment was made for multiple comparisons. Secondary analyses suggest that ventricular enlargement and age may be associated with a relatively "hypofrontal" pattern of 18FDG.
D000328:Adult; D001143:Arousal / Q000502:physiology*; D001288:Attention / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism*; D002540:Cerebral Cortex / Q000503:physiopathology*; D002908:Chronic Disease; D003847:Deoxyglucose / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D010897:Pitch Discrimination / Q000502:physiology; D012559:Schizophrenia / Q000503:physiopathology*; D014055:Tomography, Emission-Computed
D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose